Advertisement

Search Results

Advertisement



Your search for The A matches 30539 pages

Showing 51 - 100


breast cancer

Invasive Breast Cancer Incidence by Race, Stage, and Hormone-Receptor Status in U.S. Women With Breast Cancer

In a study reported in JAMA Network Open, Xu et al identified incidence of primary invasive breast cancer according to race/ethnicity, disease stage, and hormone receptor status among U.S. women with breast cancer aged 20 to 49 years diagnosed between 2000 and 2019. Study Details The study used...

survivorship
pain management

Can Physical Activity Lessen Pain Intensity in Cancer Survivors?

Physical activity may help lessen the intensity of pain in cancer survivors, according to a recent study published by Swain et al in Cancer. Background Current U.S. guidelines regarding physical activity recommend that individuals receive 150 to 300 minutes of moderate-intensity exercise per week,...

breast cancer
issues in oncology

Low-Dose Positron-Emission Mammography May Improve Breast Cancer Detection

Low-dose positron-emission mammography (PEM) may provide high sensitivity for detecting breast cancer and significantly reduce the likelihood of false-positive results, according to a recent study published by Freitas et al in Radiology: Imaging Cancer. The innovative breast imaging technique may...

lung cancer

Osimertinib vs Sequential Gefitinib/Osimertinib in Advanced EGFR-Mutant NSCLC

As reported in the Journal of Clinical Oncology by Jordi Remon, MD, PhD, and colleagues, the final analysis of overall survival in the phase II EORTC APPLE trial showed no significant difference between the strategies of upfront osimertinib vs sequential gefitinib/osimertinib in previously...

Expert Point of View: Aaron T. Gerds, MD, MS

Aaron T. Gerds, MD, MS, Assistant Professor of Hematology and Oncology at the Cleveland Clinic Foundation in Ohio, served as a press briefing moderator at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. He was enthusiastic about the potential for an all-oral AAA...

leukemia

All-Oral Regimen Feasible and Effective in Acute Promyelocytic Leukemia, Study Finds

An all-oral regimen for newly diagnosed acute promyelocytic leukemia (APL) was shown to be “highly effective and safe,” eliminating the need for chemotherapy altogether in many patients, Hong Kong researchers reported at the 2023 American Society of Hematology (ASH) Annual Meeting &...

solid tumors
survivorship
cardio-oncology

Novel Biomarker in Cancer Survivors May Be Linked to Higher Risk of Mortality

Elevated N-terminal pro–brain natriuretic peptide (NT-proBNP) levels may be associated with a higher risk of mortality among cancer survivors, according to a recent study published by Cao et al in the Journal of the National Cancer Institute. NT-proBNP—produced in response to the stretching of...

breast cancer
genomics/genetics
issues in oncology

Shedding Light on Mechanisms Behind Fulvestrant Resistance in Advanced ER-Positive Breast Cancer

Researchers may have uncovered the factors contributing to hormone therapy resistance in some patients with advanced estrogen receptor (ER)-positive breast cancer, according to a recent study published by Kingston et al in Cancer Discovery. The findings may indicate drugs currently in development...

issues in oncology

Are Major Adverse Financial Events Linked to a Later-Stage Cancer Diagnosis?

Studies have shown that millions of people in the United States are financially vulnerable because of low income, limited savings, or high levels of debt. In 2021, 32% of U.S. adults reported being unable to cover an unexpected expense of $400. A recent study by researchers at the American Cancer...

prostate cancer

High-Risk Localized Prostate Cancer: Survival Benefit With Long-Term ADT and Dose-Escalated Radiation Therapy

Men with high-risk localized prostate cancer had a significant survival benefit when treated with a more intensified regimen of dose-escalated radiation therapy plus long-term androgen-deprivation therapy (ADT) vs standard radiation therapy plus ADT, according to long-term follow-up from the...

colorectal cancer

Multiplex Analysis of Intratumoral Immune Infiltrate and Prognosis in Colorectal Cancer

In an analysis reported by Frei et al in The Lancet Oncology, multiplex immunofluorescence staining of tissue microarrays of samples from patients with stage II to III colorectal cancer showed that densities of CD8-positive and Foxp3-positive cells were associated with recurrence-free interval. As...

hematologic malignancies
immunotherapy

EBV-Positive Posttransplantation Lymphoproliferative Disease: T-Cell Immunotherapy Efficacy

In the phase III ALLELE trial reported in The Lancet Oncology, Mahadeo et al found that the Epstein-Barr virus (EBV)-specific T-cell immunotherapy tabelecleucel produced high response rates—and few of the toxicities associated with other adoptive T-cell therapies—in allogeneic hematopoietic stem...

myelodysplastic syndromes

MRD Markers and Outcomes in Patients With MDS After Stem Cell Transplant

In a Scandinavian study reported in the Journal of Clinical Oncology, Tobiasson et al found that individual-patient measurable residual disease (MRD) could be assessed by next-generation sequencing (NGS) and droplet digital polymerase chain reaction (ddPCR) to predict outcomes in patients with...

colorectal cancer
issues in oncology

Machine-Learning Model May Predict Oxaliplatin Benefit in Colon Cancer

The novel COLOXIS machine learning model may accurately predict which patients with colon cancer are most likely to derive benefit from oxaliplatin, according to a recent study published by Chen et al in the Journal of Clinical Oncology. The findings could ultimately allow physicians to better...

multiple myeloma
issues in oncology

Ephrin B2 Identified as Potential Therapeutic Target to Inhibit Multiple Myeloma Growth

Researchers have discovered that the ephrin B2 protein may drive the growth and development of multiple myeloma and uncovered that blocking part of the protein’s unique signaling pathway may inhibit progression of the disease, according to a recent study published by Sasine et al in Cancer...

global cancer care

How ASCO’s Regional Councils Are Having an International Impact on Patients With Cancer

In September 2023, ASCO announced the establishment of its fourth regional council, the Central and Eastern European Regional Council, which includes representatives from 17 countries, with the goal of expanding ASCO’s mission globally to “conquer cancer through research, education, and promotion...

multiple myeloma

DREAMM-7 Confirms Benefit of Triplet Regimen in Relapsed or Refractory Multiple Myeloma

Positive results were reported for belantamab mafodotin-blmf plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma, according to data from the phase III DREAMM-7 study presented at the ASCO Plenary Series: February 2024 Session (Abstract 439572). DREAMM-7...

gastrointestinal cancer
gastroesophageal cancer

Fruquintinib Plus Paclitaxel as Second-Line Treatment for Gastric or Gastroesophageal Junction Cancer

The combination of fruquintinib and paclitaxel is a potential new second-line treatment for patients with advanced gastric or gastroesophageal junction cancer, according to data presented during the ASCO Plenary Series: February 2024 Session (Abstract 438780). Results of the phase III FRUTIGA...

breast cancer
supportive care

Skin Microbiome and Severe Radiodermatitis in Patients With Breast Cancer

In a German single-institution study reported in JAMA Oncology, Hülpüsch et al identified skin microbiome characteristics associated with severe radiodermatitis in women receiving adjuvant radiotherapy for breast cancer. Study Details The study included 20 consecutively enrolled women who received...

prostate cancer

Localized Prostate Cancer: Functional Outcomes After Specific Treatments

In an observational cohort study reported in JAMA, Al Awamlh et al identified adverse functional outcomes after localized prostate cancer treatment among patients with favorable- and unfavorable-prognosis disease.  Study Details The study included 2,445 patients from five SEER (Surveillance,...

issues in oncology
prostate cancer
bladder cancer
kidney cancer

Insufficiencies Discovered in Patient-Reported Outcomes Data From Genitourinary Cancer Clinical Trials

Investigators may have found a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials, according to a recent study published by Paravathaneni et al in eClinicalMedicine. Background Genitourinary cancers affect over 444,000...

breast cancer
issues in oncology

High Reoperation Rates Following Breast-Conserving Surgery May Increase Cost of Care and Risk of Complications

Investigators have uncovered high rates of reoperation following initial breast-conserving surgery in patients with breast cancer that may contribute to increased costs of cancer care and a higher risk of postoperative complications, according to a recent study published by Kim et al in the Annals...

bladder cancer

Andrea B. Apolo, MD, on Urothelial Carcinoma: Phase III Findings on Pembrolizumab vs Observation

Andrea B. Apolo, MD, of the National Cancer Institute, National Institutes of Health, discusses the results of the AMBASSADOR Alliance A031501 study, which showed adjuvant pembrolizumab improved disease-free survival vs observation for patients with high-risk muscle-invasive urothelial carcinoma...

bladder cancer

Rohit K. Jain, MD, MPH, on Urothelial Carcinoma: New Data on Cabozantinib Plus Pembrolizumab

Rohit K. Jain, MD, MPH, of the H. Lee Moffitt Cancer Center and Research Institute, discusses a novel phase II trial of pembrolizumab plus cabozantinib. The study showed this combination may be efficacious as first-line therapy for patients with metastatic urothelial carcinoma, including those who...

issues in oncology

Reflections on Cancer’s Toll on My Family

Over the past 2 years, my family and I have experienced firsthand the challenges of cancer. In the spring of 2021, my mother was diagnosed with stage IIB pancreatic cancer. She died in mid-2023 after developing metastatic disease, including peritoneal carcinomatosis. The experience has caused me to ...

prostate cancer

Metastatic Castration-Resistant Prostate Cancer: LuPSMA vs Cabazitaxel

As reported in The Lancet Oncology by Michael S. Hofman, MBBS, and colleagues, the Australian phase II TheraP trial has shown similar overall survival with lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) vs cabazitaxel in patients with prostate-specific membrane...

leukemia

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

In a single-center phase I/II study reported in the Journal of Clinical Oncology, Nicholas J. Short, MD, and colleagues found that treatment with azacitidine, venetoclax, and gilteritinib produced a high response rate in newly diagnosed patients with FLT3-mutated acute myeloid leukemia (AML);...

skin cancer

Triplet Without or With Ipilimumab in Kidney Transplant Recipients With Advanced Cutaneous Cancers

In a small phase I/II trial reported in the Journal of Clinical Oncology, Schenk et al found that treatment with tacrolimus, prednisone, and nivolumab without or with ipilimumab produced few responses in kidney transplant recipients with advanced skin cancers, with treatment-related allograft loss...

hematologic malignancies
issues in oncology
supportive care

Antihypertensive Drug Combinations May Help Reduce Blood Pressure in Patients Receiving Ibrutinib

Combination therapy with two or more antihypertensive drugs may reduce blood pressure in patients receiving ibrutinib, according to a recent study published by Samples et al in Blood Advances. Background Ibrutinib was the first Bruton tyrosine kinase (BTK) inhibitor to receive U.S. Food and Drug...

leukemia
hematologic malignancies
issues in oncology

BTK Degrader May Target Treatment Resistance in Patients With CLL

Researchers have identified a next-generation Bruton’s tyrosine kinase (BTK) degrader that could help patients with chronic lymphocytic leukemia (CLL) and related hematologic malignancies overcome treatment resistance, according to a recent study published by Montoya et al in Science. The findings...

bladder cancer

Bishoy M. Faltas, MD, on Upper Tract Urothelial Carcinoma: How Biology Shapes Therapy

Bishoy M. Faltas, MD, of Weill Cornell Medicine, discusses the biology of upper tract urothelial carcinoma and how it affects treatment, noting that most of these tumors are luminal papillary with a T-cell–depleted immune contexture driven by FGFR3 activation. Phase III trials have confirmed the...

kidney cancer

Andrew Johns, MD, on Clear Cell Renal Cell Carcinoma: Data on Tivozanib in Pretreated Patients

Andrew Johns, MD, of The University of Texas MD Anderson Cancer Center, discusses efficacy, safety, and tolerability data on tivozanib. The agent yielded a modest clinical benefit in a minority of patients with advanced clear cell renal cell carcinoma who received prior immune checkpoint–based...

bladder cancer
genomics/genetics

David H. Aggen, MD, PhD, on Advanced Bladder Cancer: HER2 and PD-L1 Immunohistochemistry and HER2 Genomic Alterations

David H. Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses reportedly the first data to describe an inverse correlation between HER2 immunohistochemistry expression and PD-L1 combined positive score. According to Dr. Aggen, these and other findings by his team may provide a...

solid tumors

Enrique Grande, MD, on Adrenocortical Carcinoma: Phase II Results on Cabozantinib Plus Atezolizumab

Enrique Grande, MD, of MD Anderson Cancer Center Madrid, discusses findings from the CABATEN/GETNE-T1914 study, in which cabozantinib plus atezolizumab showed modest activity in patients with locally advanced or metastatic adrenocortical carcinoma, a rare malignancy with a poor prognosis and...

bladder cancer

Michiel S. Van Der Heijden, MD, PhD, on Metastatic Urothelial Carcinoma: Phase III Trial Data on Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy

Michiel S. Van Der Heijden, MD, PhD, of the Netherlands Cancer Institute, discusses phase III results from the global EV-302 study, showing that enfortumab vedotin-ejfv plus pembrolizumab improves outcomes in patients with previously untreated locally advanced metastatic urothelial carcinoma...

prostate cancer

Intensification of ADT in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer After Radical Prostatectomy

As reported in the Journal of Clinical Oncology by Aggarwal et al, interim analysis of the phase III PRESTO trial showed that the addition of apalutamide as well as the addition of apalutamide plus abiraterone acetate/prednisone (AAP) to androgen-deprivation therapy (ADT) improved prostate-specific ...

lymphoma

Golidocitinib in Relapsed or Refractory Peripheral T-Cell Lymphoma

In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed activity in patients with relapsed or refractory peripheral T-cell lymphoma. Study Details In the trial, 104 patients from sites in...

head and neck cancer

HPV-Related Oropharyngeal Carcinoma: Tumor Hypoxia–Directed Treatment

In a single-institution phase II trial reported in the Journal of Clinical Oncology, Nancy Y. Lee, MD, and colleagues found that tumor hypoxia is a promising marker for radiotherapy dose among patients receiving chemoradiotherapy for human papillomavirus (HPV)-related oropharyngeal carcinoma. As...

cardio-oncology

Cardio-Oncology Is a Growing Subspecialty, but Where Are the Oncologists?

It has been almost 20 years since the approval of trastuzumab for the treatment of early-stage, HER2-positive breast cancer. I remember returning from the 2005 ASCO Annual Meeting excited to offer patients a treatment that led to significant improvement in clinical outcomes. However, within a short ...

global cancer care
solid tumors

Global Cancer Burden May Be Growing Amidst Mounting Need for Cancer Services

The World Health Organization’s (WHO) cancer agency, the International Agency for Research on Cancer (IARC), has released updated findings of the current global burden of cancer alongside World Cancer Day on February 4, 2023. The WHO indicated that a majority of countries do not adequately finance...

lung cancer
issues in oncology

Osimertinib May Offer Survival Benefit Over Immunotherapy in Some Patients With Unresectable NSCLC

Investigators have found that the targeted therapy osimertinib may be associated with improved progression-free survival when administered after chemotherapy and radiation in patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, according to a...

prostate cancer

Sumanta K. Pal, MD, on Prostate Cancer: Impact of the Microbiome on Immune Therapy

Sumanta K. Pal, MD, of City of Hope, discusses the ways in which the composition of the gut microbiome may impact the outcome of immune therapy. Methods such as fecal microbiome transplant hold promise as a means of augmenting the effect of treatment and, according to Dr. Pal, potentially...

kidney cancer
immunotherapy

Saby George, MD, on Clear Cell Kidney Cancer: Subcutaneous vs Intravenous Nivolumab

Saby George, MD, of Roswell Park Comprehensive Cancer Center, discusses pharmacokinetics, efficacy, and safety results from CheckMate 67T, a phase III trial comparing the use of subcutaneous vs intravenous nivolumab in patients with advanced or metastatic clear cell renal cell carcinoma who have...

prostate cancer

Actinium-225–PSMA Radioligand Therapy for Prostate Cancer

In a retrospective study (WARMTH Act) reported in The Lancet Oncology, Sathekge et al found that actinium-225–prostate-specific membrane antigen (PSMA) radioligand therapy showed activity in patients with metastatic castration-resistant prostate cancer.   Study Details The study consisted of 448...

survivorship
cardio-oncology

Survivors of Childhood Cancer With High Anthracycline Exposure: Can a Beta-Blocker Improve Cardiac Function?

In a U.S./Canadian phase IIb trial (PREVENT-HF) reported in The Lancet Oncology, Armenian et al found that the beta-blocker carvedilol did not significantly improve cardiac function—measured as standardized left ventricular wall thickness–dimension ratio Z score (LVWT/Dz)—vs placebo in survivors of ...

issues in oncology
lung cancer

Sotorasib, the Poster Child for Project Optimus: Truths and Fantasies

In January 2021, two of us wrote in these pages about our field’s pressing need to pivot away from identifying and deploying the maximum tolerated dose (MTD) when it comes to targeted oncology therapies.1 We argued that, instead, one should be looking for the “optimal dose”—the dose that best...

skin cancer
issues in oncology

Report Sheds Light on Critical Pathway Responsible for Treatment Resistance in Melanoma

Researchers may have uncovered a novel epigenetic pathway involved in the development of treatment resistance in melanoma and a chemical reagent that may be effective in resensitizing treatment-resistant tumors to targeted therapies, according to a recent study published by Wu et al in The Journal...

issues in oncology
cost of care

Effects of Switch to High-Deductible Health Plans for Patients With Cancer

In a study reported in JAMA Oncology, Trad et al found that individuals with cancer in the United States who were switched from low- to high-deductible employer-sponsored health plans had higher out-of-pocket costs but no reduction in the number of oncologist visits; these patients, however, had...

lung cancer

Addition of Nivolumab to Chemotherapy in EGFR-Mutant Metastatic NSCLC After Disease Progression on Prior Therapy

As reported in the Journal of Clinical Oncology by Tony Mok, MD, FRCPC, FASCO, and colleagues, final results of the primarily Asian phase III CheckMate 722 trial showed no progression-free survival benefit with the addition of nivolumab to chemotherapy in patients with EGFR-mutant metastatic...

breast cancer

Addition of Palbociclib to Letrozole in ER-Positive, HER2-Negative Advanced Breast Cancer: Overall Survival in PALOMA-2

As reported in the Journal of Clinical Oncology by Dennis J. Slamon, MD, PhD, and colleagues, the phase III PALOMA-2 trial showed no overall survival benefit with the addition of palbociclib to letrozole in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer with no...

Advertisement

Advertisement




Advertisement